Key Takeaways
- • The Russell Microcap Index has surged more than 46 percent over the past year as of June 8, 2026, significantly outperforming large-cap equities and prompting institutional investor reassessment of previously neglected microcap allocations.
- • Microcap stocks, defined as companies with market capitalizations around $300 million or less, are benefiting from falling borrowing costs, widening valuation spreads between cheap and expensive stocks, strength in biotech and defense sectors, and increased deal activity.
- • Christopher Tessin, co-founder of Acuitas Investments (managing $1.75 billion in institutional assets), identifies microcaps as "the richest place for active management in equities," yet notes that most institutional plans remain under-allocated or entirely unallocated to the sector.
- • A structural paradox is constraining microcap capital flows: while microcaps offer genuine alpha opportunities, portfolio managers face benchmark pressure to maintain large-cap exposure, particularly in mega-tech stocks, to avoid underperformance relative to indices.
Summary
Microcap equities are experiencing a sharp performance inflection relative to large-cap stocks, forcing institutional investors to reconsider long-standing allocation decisions that have favored mega-cap technology companies. The Russell Microcap Index has delivered returns exceeding 46 percent over the past twelve months, substantially outpacing the broader equity market and raising questions about whether allocators have systematically under-invested in the smallest tier of publicly traded companies.
The performance rally reflects multiple tailwinds converging in the microcap space. Declining interest rates have reduced borrowing costs for smaller, capital-constrained firms. Simultaneously, valuation dispersion has widened across the market, creating opportunities for active managers to exploit pricing gaps between expensive growth stocks and undervalued microcap names. Sector-specific strength in biotech and defense has also lifted the broader microcap cohort, while elevated merger and acquisition activity is driving valuations higher across smaller-cap platforms.
Despite compelling performance metrics, capital allocation patterns reveal a notable disconnect. Christopher Tessin, co-founder of Acuitas Investments—which manages $1.75 billion across institutional small-cap mandates—characterizes microcaps as offering the highest opportunity set for active management within equities. Yet he observes that institutional plans remain "either under-allocated or not allocated at all" to the sector. This allocation shortfall stems partly from structural constraints: portfolio managers, even those skeptical of artificial intelligence valuations, face internal and external pressure to maintain exposure to mega-cap technology stocks to prevent benchmark drag and relative performance deterioration.
This dynamic creates an unusual market tension. While the smallest-cap opportunity set appears genuinely compelling from a fundamental perspective, the gravitational pull of mega-cap tech stocks and high-profile initial public offerings continues to dominate institutional decision-making. The result is a paradox where measurable alpha exists in neglected corners of the market, yet competitive and performance-tracking pressures incentivize staying overweight in expensive, crowded positions.
The performance rally reflects multiple tailwinds converging in the microcap space. Declining interest rates have reduced borrowing costs for smaller, capital-constrained firms. Simultaneously, valuation dispersion has widened across the market, creating opportunities for active managers to exploit pricing gaps between expensive growth stocks and undervalued microcap names. Sector-specific strength in biotech and defense has also lifted the broader microcap cohort, while elevated merger and acquisition activity is driving valuations higher across smaller-cap platforms.
Despite compelling performance metrics, capital allocation patterns reveal a notable disconnect. Christopher Tessin, co-founder of Acuitas Investments—which manages $1.75 billion across institutional small-cap mandates—characterizes microcaps as offering the highest opportunity set for active management within equities. Yet he observes that institutional plans remain "either under-allocated or not allocated at all" to the sector. This allocation shortfall stems partly from structural constraints: portfolio managers, even those skeptical of artificial intelligence valuations, face internal and external pressure to maintain exposure to mega-cap technology stocks to prevent benchmark drag and relative performance deterioration.
This dynamic creates an unusual market tension. While the smallest-cap opportunity set appears genuinely compelling from a fundamental perspective, the gravitational pull of mega-cap tech stocks and high-profile initial public offerings continues to dominate institutional decision-making. The result is a paradox where measurable alpha exists in neglected corners of the market, yet competitive and performance-tracking pressures incentivize staying overweight in expensive, crowded positions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.